PHAIT

PHAIT is pioneering a novel approach to oncology by focusing on prevention rather than treatment, targeting the world's leading cancer killer, lung cancer. Its lead asset is oral Iloprost, a well-tolerated drug with decades of clinical use in other indications, which demonstrated efficacy in reducing pre-cancerous bronchial dysplasia in a Phase II study. The company holds exclusive worldwide licenses and method-of-treatment patents, positioning it to address a vast, underserved market of at-risk individuals. As a private, pre-revenue entity, PHAIT is planning further clinical studies to advance its chemoprevention strategy.

Strategic repurposing and oral formulation of Iloprost, a prostacyclin derivative with anti-tumorigenic properties, for sustained systemic delivery to achieve chemoprevention.

The competitive landscape for pharmacological lung cancer chemoprevention is nascent, with few late-stage candidates. PHAIT's main competition currently is active surveillance (CT screening). Its primary competitive advantages are the strong safety profile of its repurposed drug and compelling Phase II data, protected by method-of-use patents.